Literature DB >> 22610021

Caution in making inferences from FDA's Adverse Event Reporting System.

Michael Auerbach, Robert C Kane.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22610021     DOI： 10.2146/ajhp120138

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  9 in total

Review 1.  Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?

Authors:  Christiane Michel; Emil Scosyrev; Michael Petrin; Robert Schmouder
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

2.  Intravenous iron and safety: is the end of the debate on the horizon?

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

Review 3.  Safety of intravenous iron formulations: facts and folklore.

Authors:  Michael Auerbach; Iain C Macdougall
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

4.  A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.

Authors:  Keith B Hoffman; Mo Dimbil; Nicholas P Tatonetti; Robert F Kyle
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606

5.  Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data.

Authors:  Pankdeep Chhabra; Xing Chen; Sheila R Weiss
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

Review 6.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738

7.  Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.

Authors:  Toshiyuki Sakaeda; Kaori Kadoyama; Keiko Minami; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2014-03-15       Impact factor: 3.738

8.  Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.

Authors:  James B Wetmore; Eric D Weinhandl; Jincheng Zhou; David T Gilbertson
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

9.  Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.

Authors:  Kim-Lien Nguyen; Takegawa Yoshida; Nikhita Kathuria-Prakash; Islam H Zaki; Csanad G Varallyay; Scott I Semple; Rola Saouaf; Cynthia K Rigsby; Sokratis Stoumpos; Kevin K Whitehead; Lindsay M Griffin; David Saloner; Michael D Hope; Martin R Prince; Mark A Fogel; Mark L Schiebler; Giles H Roditi; Aleksandra Radjenovic; David E Newby; Edward A Neuwelt; Mustafa R Bashir; Peng Hu; J Paul Finn
Journal:  Radiology       Date:  2019-10-22       Impact factor: 11.105
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.